In:
Oncology Research and Treatment, S. Karger AG, Vol. 45, No. 10 ( 2022), p. 598-607
Abstract:
〈 b 〉 〈 i 〉 Aim: 〈 /i 〉 〈 /b 〉 The present exploratory study investigated the diagnostic value of inflammatory markers in patients with breast cancer to predict anti-tumour treatment-related cardiac events. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Twenty-one patients with breast cancer were enrolled in this prospective observational study and followed over 6 months. Transthoracic echocardiography and measurement of cardiac (N-terminal prohormone of brain natriuretic peptide (NT-proBNP), troponin I (TnI)) and inflammatory biomarkers (vascular adhesion molecule 1 (VCAM-1), soluble suppression of tumorigenesis-2 (sST2), adiponectin) was performed at 3-month intervals (baseline, follow-up, final visit). Cardiac events were defined as decrease in left ventricular ejection fraction (LVEF, decrease by 10% or & #x3c;50%) or increase in global longitudinal strain (GLS, increase by 15% or & #x3e; −16%), as a more sensitive marker of LV function. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Cardiac deterioration was observed in 9 out of 21 patients (event group). While LVEF did not differ significantly between the two groups (event vs. no event) at any visit, GLS was significantly higher during follow-up (follow-up: event −16 ± 3.3% vs. no event −18 ± 1.6%, 〈 i 〉 p 〈 /i 〉 = 0.04; final visit: event −16 ± 2.1% vs. no event −19 ± 1.9%, 〈 i 〉 p 〈 /i 〉 = 0.003). NT-proBNP was numerically higher in patients with a cardiac event during all visits, with NT-proBNP negatively correlated with LVEF and MAPSE (both 〈 i 〉 r 〈 /i 〉 = −0.33, 〈 i 〉 p 〈 /i 〉 = 0.02), whereas GLS ( 〈 i 〉 r 〈 /i 〉 = 0.40, 〈 i 〉 p 〈 /i 〉 = 0.006), TnI ( 〈 i 〉 r 〈 /i 〉 = 0.44, 〈 i 〉 p 〈 /i 〉 = 0.001), and VCAM-1 ( 〈 i 〉 r 〈 /i 〉 = 0.48, 〈 i 〉 p 〈 /i 〉 = 0.003) showed a positive association with NT-proBNP. In comparison, higher VCAM-1 and sST2 concentrations were detected in the event group at both baseline and the final visit, with a significant difference for baseline (VCAM-1: 〈 i 〉 p 〈 /i 〉 = 0.02; sST2: 〈 i 〉 p 〈 /i 〉 = 0.03). Adiponectin was also lower in patients with a treatment-related event. Thresholds for VCAM-1 & #x3e;762 ng/mL and sST2 & #x3e;18.7 ng/mL, as detected by ROC analysis, correlated best with the primary endpoint. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Cardiac events during anti-tumour treatment in patients with breast cancer are relatively common. Inflammatory markers such as VCAM-1 or sST2 were associated with an increased likelihood for occurrence of a treatment-related event, which may therefore hold the promise to better identify patients at high risk.
Type of Medium:
Online Resource
ISSN:
2296-5270
,
2296-5262
Language:
English
Publisher:
S. Karger AG
Publication Date:
2022
detail.hit.zdb_id:
2749752-5
Permalink